Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Gannex Pharma Co., Ltd.
Modality
UNKNOWN
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04692025CT.gov Study to Evaluate the Effect of Food on the Pharmacokinetics of ASC41 in Healthy Volunteers | — | Completed | — | — | — |
NCT04686994CT.gov Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hyperlipidemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| asc41 (this asset) | Gannex Pharma Co., Ltd. | P1 | CCC · 52 |
| Atorvastatin | Poznan University of Medical Sciences | P4 | BBB |
| Rosuvastatin | Nanjing First Hospital, Nanjing Medical University | P4 | BBB |
| Pravastatin | University of North Carolina, Chapel Hill | P4 | BBB |
| Ezetimibe | NewAmsterdam Pharma | P4 | BBB |
| Darunavir | University of Colorado, Denver | P4 | BB |
| Fenofibrate | Ospedale di Circolo - Fondazione Macchi | P4 | BB |
| NORVIR | University of Colorado, Denver | P4 | BB |
| Simvastatin | National University Hospital, Singapore | P4 | BB |
+27 more in the Hyperlipidemia cohort
Other indications for asc41
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P2 | B · 58 |
| Metabolic Dysfunction-Associated Steatohepatitis | — | P2 | CCC · 53 |
| Obesity Disorder | — | P1 | CC · 44 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. asc41 in Hyperlipidemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/asc41-hyperlipidemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →